Wire · opportunities
FDA TEMPO Pilot Lets Generative-AI Medical Devices Launch Without Marketing Authorization
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
The FDA has initiated the TEMPO pilot program allowing generative AI medical devices to launch without prior marketing authorization while regulators observe the technology in real-world use. The pilot includes four devices and integrates with the Medicare ACCESS model for managing chronic conditions.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You gain a rare pathway to launch generative AI medical devices without waiting for marketing authorization, opening a faster route to market under FDA's pilot. This removes a major barrier if you build AI healthcare tools tied to chronic condition management.
◆ Coverage
1 source · 4 Sep 2026
◆ Related on Wire
◆ Topics